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To the Editor:
We read the article by Kersting et al [1] on chronic
kidney disease after myeloablative allogeneic hemato-
poietic stem cell transplantation (HSCT) with great
interest. The authors reported that 23% of the patients
receiving a myeloablative conditioning regimen and
total body irradiation (TBI) developed chronic kidney
disease. The conditioning regimen consisted of cyclo-
phosphamide (6 mg/kg/day for 2 days), followed by
TBI (2  6 Gy in 2 days), with the kidneys shielded
to 2  5 Gy. The dose rate was 9 Gy/h. Chronic renal
disease after HSCT has been associated with TBI [2-
4]. The dose of 2  5 Gy to the kidneys may have
been beyond the tolerance dose for kidney failure.
Here we comment on the TBI dose and propose
a TBI regimen that possibly could result in a lower
frequency of renal disease, but still provide a high
antileukemic effect.
Recently, we reviewed the literature, compared the
results of treatments with various TBI regimens, and
determined a dose–effect relationship for renal dys-
function after TBI [5]. For intercomparison, as used
in radiotherapy, the various TBI regimens were nor-
malized (using the linear-quadratic model), and the bi-
ological effective doses (BEDs) were calculated [6]. In
this way, for each TBI regimen, the total dose, number
of fractions, and dose rate could be included in a single
BED value. We found a threshold BED of about 16 Gy
for late kidney failure [5].
To prevent renal disease, the kidneys of the pa-
tients described by Kersting et al. [1] should have
been shielded from 2  5 Gy (BED 5 28.1 Gy) to 2
 3.6 Gy (BED 5 16.6 Gy). However, shielding will
result in a lower BED not only of the shielded organ,
but also of the leukemic cells present in the tissues in
the shadow of the shielding block. The BED of the leu-
kemic cells in the region shielded to 2  3.6 Gy wasonly 9.1 Gy, whereas in the unshielded tissues it was
17.4 Gy.
With hyperfractionated TBI regimens, a relatively
high BED for leukemic cells can be obtained, whereas
shielding is relatively limited. For example, with
a scheme of 6 fractions of 2.3 Gy given over 3 days at
a dose rate of 9 Gy/h, the BED for leukemic cells is
16.6 Gy, and the BED of the kidney tissue is 26.0 Gy
(with differences in BED values from tissue-specific
parameters [5,6]). With shielding of the kidneys to 6
 1.7 Gy, the resulting BED is16.9 Gy; thus, the kidney
dose reduction is only 26%. The BED for leukemic cells
behind the shielding block remains 11.8 Gy. Thus, hy-
perfractionated TBI with proper shielding might be
useful in preventing chronic renal dysfunction.
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